UB Paderborn / Katalog / Suche / in CDI

Sortiert nach

Einfacher Volltextzugriff von (fast) überall

Installieren Sie die LibKey Nomad-Browsererweiterung und erhalten Sie von vielen Webseiten einfachen Zugriff auf lizenzierte Volltexte oder Open Access Publikationen. Mehr erfahren...

1979P phase I trial of pembrolizumab in HIV-associated Kaposi sarcoma (KS)

Annals of oncology, 2023-10, Vol.34, p.S1056-S1056

2023

Volltextzugriff (PDF)

A phase I study of intraperitoneal MCY-M11 Anti-mesothelin CAR for women with platinum resistant high grade serous adenocarcinoma of the ovary, primary peritoneum, or fallopian tube, or subjects with peritoneal mesothelioma with recurrence after prior chemotherapy

Annals of oncology, 2019-10, Vol.30, p.v531

2019

Volltextzugriff (PDF)

1308TiP - A phase I study of intraperitoneal MCY-M11 Anti-mesothelin CAR for women with platinum resistant high grade serous adenocarcinoma of the ovary, primary peritoneum, or fallopian tube, or subjects with peritoneal mesothelioma with recurrence after prior chemotherapy

Annals of oncology, 2019-10, Vol.30, p.v531-v531

2019

Volltextzugriff (PDF)

1308TiPA phase I study of intraperitoneal MCY-M11 Anti-mesothelin CAR for women with platinum resistant high grade serous adenocarcinoma of the ovary, primary peritoneum, or fallopian tube, or subjects with peritoneal mesothelioma with recurrence after prior chemotherapy

Annals of oncology, 2019-10, Vol.30 (Supplement_5)

2019

Volltextzugriff (PDF)

A phase II study of the cell cycle checkpoint kinases 1 and 2 inhibitor (LY2606368; Prexasertib monomesylate monohydrate) in sporadic high-grade serous ovarian cancer (HGSOC) and germline BRCA mutation-associated ovarian cancer (gBRCAm+ OvCa)

Annals of oncology, 2016-10, Vol.27, p.vi296-vi296

2016

Volltextzugriff (PDF)

A phase II study of the cell cycle checkpoint kinases 1 and 2 (CHK1/2) inhibitor (LY2606368; prexasertib) in sporadic triple negative breast cancer (TNBC)

Annals of oncology, 2016-10, Vol.27, p.vi71-vi71

2016

Volltextzugriff (PDF)

IMMUNE AND VIRUS‐SPECIFIC RESPONSES IN PARTICIPANTS WITH PRIMARY EFFUSION LYMPHOMA RECEIVING LENALIDOMIDE, DOSE‐ADJUSTED EPOCH, AND RITUXIMAB (EPOCH‐R 2 )

Hematological oncology, 2021-06, Vol.39 (S2)

2021

Volltextzugriff (PDF)

Prexasertib, a cell cycle checkpoint kinase 1 and 2 inhibitor, in BRCA wild-type recurrent high-grade serous ovarian cancer: a first-in-class proof-of-concept phase 2 study

The lancet oncology, 2018-02, Vol.19 (2), p.207-215

2018

Volltextzugriff (PDF)

CE: HIV-Associated Kaposi Sarcoma in the Combination Antiretroviral Therapy Era

The American journal of nursing, 2022-12, Vol.122 (12), p.32-40

2022

Volltextzugriff (PDF)

A Phase 1 trial of autologous monocytes stimulated ex vivo with Sylatron ® (Peginterferon alfa-2b) and Actimmune ® (Interferon gamma-1b) for intra-peritoneal administration in recurrent ovarian cancer

Journal of translational medicine, 2018-07, Vol.16 (1), p.196-9, Article 196

2018

Volltextzugriff (PDF)

Transcriptional landscape of Kaposi sarcoma tumors identifies unique immunologic signatures and key determinants of angiogenesis

Journal of translational medicine, 2023-09, Vol.21 (1), p.1-653, Article 653

2023

Volltextzugriff (PDF)

Use of pembrolizumab with or without pomalidomide in HIV-associated non-Hodgkin’s lymphoma

Journal for immunotherapy of cancer, 2021-02, Vol.9 (2), p.e002097

2021

Volltextzugriff (PDF)

Kaposi sarcoma herpesvirus viral load in bronchoalveolar lavage as a diagnostic marker for pulmonary Kaposi sarcoma

AIDS (London), 2024-07, Vol.38 (8), p.1172-1180

2024

Volltextzugriff (PDF)

Characteristics of patients admitted to the ICU with Kaposi sarcoma herpesvirus-associated diseases

AIDS (London), 2022-11, Vol.36 (14), p.1969-1978

2022

Volltextzugriff (PDF)

Production of a cellular product consisting of monocytes stimulated with Sylatron ® (Peginterferon alfa-2b) and Actimmune ® (Interferon gamma-1b) for human use

Journal of translational medicine, 2019-03, Vol.17 (1), p.82-82, Article 82

2019

Volltextzugriff (PDF)

Abstract B008: Survival outcomes in older people living with HIV and cancer

Cancer epidemiology, biomarkers & prevention, 2023-12, Vol.32 (12_Supplement), p.B008-B008

2023

Volltextzugriff (PDF)

Phase 1 study of intraperitoneal infusion of autologous monocytes with peginterferon alfa-2b and interferon gamma-1b in women with recurrent or refractory ovarian cancer, fallopian tube cancer, or primary peritoneal cancer

Journal of clinical oncology, 2017-05, Vol.35 (15_suppl), p.TPS3092-TPS3092

2017

Volltextzugriff (PDF)

Phase I Study of Lenalidomide Combined with Dose-Adjusted EPOCH and Rituximab (EPOCH-R2) in Primary Effusion Lymphoma in Participants with or without HIV (NCT02911142)

Blood, 2020-11, Vol.136 (Supplement 1), p.8-9

2020

Volltextzugriff (PDF)

Abstract 5000: Cell cycle checkpoint kinase (CHK)1 inhibition induces immune modulation in recurrent BRCA wild-type high-grade serous ovarian cancer (HGSOC) patients

Cancer research (Chicago, Ill.), 2019-07, Vol.79 (13_Supplement), p.5000-5000

2019

Volltextzugriff (PDF)

Abstract CT159: A phase 1 study of intraperitoneal MCY-M11 therapy for women with platinum resistant high grade serous adenocarcinoma of the ovary, primary peritoneum, or fallopian tube, or subjects with peritoneal mesothelioma with recurrence after prior chemotherapy

Cancer research (Chicago, Ill.), 2019-07, Vol.79 (13_Supplement), p.CT159-CT159

2019

Volltextzugriff (PDF)

A phase I trial of pomalidomide in combination with liposomal doxorubicin in patients with Kaposi sarcoma with or without other KSHV-associated diseases

Journal of clinical oncology, 2020-05, Vol.38 (15_suppl), p.11552-11552

2020

Volltextzugriff (PDF)

1 – 25 von 34

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(34)
Mit Volltextzugriff
(30)

Publikationsform

Artikel
(34)

Sprache

Englisch
(34)

Erscheinungsjahr

n.n

Thema

15 weitere anzeigen...

Weniger anzeigen...

Zeitschrift / Serie

5 weitere anzeigen...

Weniger anzeigen...

Neu hinzugefügt

... seit 30 Tagen
(1)
... seit 90 Tagen
(2)

Menü

Weitere Dienste

Einstellungen

1979P phase I trial of pembrolizumab in HIV-associated Kaposi sarcoma (KS)

A phase I study of intraperitoneal MCY-M11 Anti-mesothelin CAR for women with platinum resistant high grade serous adenocarcinoma of the ovary, primary peritoneum, or fallopian tube, or subjects with peritoneal mesothelioma with recurrence after prior chemotherapy

1308TiP - A phase I study of intraperitoneal MCY-M11 Anti-mesothelin CAR for women with platinum resistant high grade serous adenocarcinoma of the ovary, primary peritoneum, or fallopian tube, or subjects with peritoneal mesothelioma with recurrence after prior chemotherapy

1308TiPA phase I study of intraperitoneal MCY-M11 Anti-mesothelin CAR for women with platinum resistant high grade serous adenocarcinoma of the ovary, primary peritoneum, or fallopian tube, or subjects with peritoneal mesothelioma with recurrence after prior chemotherapy

A phase II study of the cell cycle checkpoint kinases 1 and 2 inhibitor (LY2606368; Prexasertib monomesylate monohydrate) in sporadic high-grade serous ovarian cancer (HGSOC) and germline BRCA mutation-associated ovarian cancer (gBRCAm+ OvCa)

A phase II study of the cell cycle checkpoint kinases 1 and 2 (CHK1/2) inhibitor (LY2606368; prexasertib) in sporadic triple negative breast cancer (TNBC)

IMMUNE AND VIRUS‐SPECIFIC RESPONSES IN PARTICIPANTS WITH PRIMARY EFFUSION LYMPHOMA RECEIVING LENALIDOMIDE, DOSE‐ADJUSTED EPOCH, AND RITUXIMAB (EPOCH‐R 2 )

Prexasertib, a cell cycle checkpoint kinase 1 and 2 inhibitor, in BRCA wild-type recurrent high-grade serous ovarian cancer: a first-in-class proof-of-concept phase 2 study

CE: HIV-Associated Kaposi Sarcoma in the Combination Antiretroviral Therapy Era

A Phase 1 trial of autologous monocytes stimulated ex vivo with Sylatron ® (Peginterferon alfa-2b) and Actimmune ® (Interferon gamma-1b) for intra-peritoneal administration in recurrent ovarian cancer

Transcriptional landscape of Kaposi sarcoma tumors identifies unique immunologic signatures and key determinants of angiogenesis

Use of pembrolizumab with or without pomalidomide in HIV-associated non-Hodgkin’s lymphoma

Kaposi sarcoma herpesvirus viral load in bronchoalveolar lavage as a diagnostic marker for pulmonary Kaposi sarcoma

Characteristics of patients admitted to the ICU with Kaposi sarcoma herpesvirus-associated diseases

Production of a cellular product consisting of monocytes stimulated with Sylatron ® (Peginterferon alfa-2b) and Actimmune ® (Interferon gamma-1b) for human use

Abstract B008: Survival outcomes in older people living with HIV and cancer

Intraperitoneal Monocytes plus IFNs as a Novel Cellular Immunotherapy for Ovarian Cancer: Mechanistic Characterization and Results from a Phase I Clinical Trial

Cancer Immunotherapy Trials Network 12: Pembrolizumab in HIV-Associated Kaposi Sarcoma

Phase 1 study of intraperitoneal infusion of autologous monocytes with peginterferon alfa-2b and interferon gamma-1b in women with recurrent or refractory ovarian cancer, fallopian tube cancer, or primary peritoneal cancer

Phase I Study of Lenalidomide Combined with Dose-Adjusted EPOCH and Rituximab (EPOCH-R2) in Primary Effusion Lymphoma in Participants with or without HIV (NCT02911142)

Abstract 5000: Cell cycle checkpoint kinase (CHK)1 inhibition induces immune modulation in recurrent BRCA wild-type high-grade serous ovarian cancer (HGSOC) patients

Abstract CT159: A phase 1 study of intraperitoneal MCY-M11 therapy for women with platinum resistant high grade serous adenocarcinoma of the ovary, primary peritoneum, or fallopian tube, or subjects with peritoneal mesothelioma with recurrence after prior chemotherapy

Intraperitoneal monocytes plus interferons as a novel cellular immunotherapy for ovarian cancer: mechanistic characterization and results from a phase I clinical trial

A phase I trial of pomalidomide in combination with liposomal doxorubicin in patients with Kaposi sarcoma with or without other KSHV-associated diseases

Correction: Intraperitoneal Monocytes plus IFNs as a Novel Cellular Immunotherapy for Ovarian Cancer: Mechanistic Characterization and Results from a Phase I Clinical Trial

Suchergebnisse filtern